Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADA | P00813 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8175179 | 1.00 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL20794210 | 1.00 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL24499895 | 1.00 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL12832016 | 1.00 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL13690449 | 0.83 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL22820040 | 0.83 | CYP2C19 (0.42) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL13939562 | 0.83 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL7162148 | 0.83 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL19242531 | 0.81 | ADORA3 (0.42) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL19941993 | 0.81 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2021-08-05 | — | — | US | disclosed |
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| EP-2287613-A2 | Detection, monitoring and treatment of cancer | THE OPEN UNIVERSITY (GB) | 2011-02-23 | — | — | EP | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
| EP-1806585-A1 | Detection, monitoring and treatment of cancer | THE OPEN UNIVERSITY (GB) | 2007-07-11 | — | — | EP | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0216511-B1 | Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxycytidine | US COMMERCE (US) | 1993-10-27 | — | — | EP | disclosed |
| EP-0216510-B1 | Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine | US COMMERCE (US) | 1993-10-27 | — | — | EP | disclosed |
| US-5254539-A | Method of treating HIV with 2',3'-dideoxyinosine | U.S. GOVERNMENT, DEPT. OF HEALTH AND HUMAN SERVICES, C/O NATIONAL INSTITUTES OF HEALTH (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4861759-A | Antiviral compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-08-29 | — | — | US | disclosed |
| US-4704357-A | TESTING DRUGS FOR EFFICARY AGAINST AIDS VIRUS | UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0216510-A2 | Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1987-04-01 | — | — | EP | disclosed |
| EP-0216511-A2 | Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxycytidine | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | PCSK9, PCSK7, PDE3A | PI4KA 3824/4885PI4K2B 3836/4885PI4K2A 3704/4885 |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | TERT, POLRMT, POLI | PI4KA 975/4885PI4K2B 2197/4885PI4K2A 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.